Editing Oncolytics Biotech Inc.
The edit can be undone. Please check the comparison below to verify that this is what you want to do, and then publish the changes below to finish undoing the edit.
| Latest revision | Your text | ||
| Line 1: | Line 1: | ||
== Summary == | == Summary == | ||
Oncolytics Biotech is a Canadian development-stage biopharmaceutical company that focuses on the discovery and development of pharmaceutical products for cancer treatment, specifically with the aim of weakening | Oncolytics Biotech is a Canadian development-stage biopharmaceutical company that focuses on the discovery and development of pharmaceutical products for cancer treatment, specifically with the aim of weakening tumour defence mechanisms. Oncolytics Biotech aims to use immunotherapeutics - a branch of biological therapies that use synthetic substances to activate the immune system for stronger responses. This approach proposes many new treatments that will support the immune system in a more powerful fight against cancer. The company's lead product is Pelareorep, simply put, Pelareorep is an oncolytic virus that causes tumour cells to burst and activates multiple immune system entities. | ||
Oncolytics Biotech has also decided to embark on a co-developmental journey with Merck KGaA and Pfizer to combine Pelareorep with Paclitaxel, a chemotherapy medication, and Avelumab, an anti-cancer antibody medication. This combination is being tested because oncolytic viruses, such as Pelareorep, have the potential to enhance existing cancer treatments like Paclitaxel and Avelumab, leading to the elimination of resistant cancer cells and reducing cancer relapses. Oncolytics Biotech is conducting experiments on breast cancer cells using Pelareorep and Pfizer's drug Bavencio (Avelumab). | Oncolytics Biotech has also decided to embark on a co-developmental journey with Merck KGaA and Pfizer to combine Pelareorep with Paclitaxel, a chemotherapy medication, and Avelumab, an anti-cancer antibody medication. This combination is being tested because oncolytic viruses, such as Pelareorep, have the potential to enhance existing cancer treatments like Paclitaxel and Avelumab, leading to the elimination of resistant cancer cells and reducing cancer relapses. Oncolytics Biotech is conducting experiments on breast cancer cells using Pelareorep and Pfizer's drug Bavencio (Avelumab). | ||
== Operations: == | == Operations: == | ||
| Line 66: | Line 36: | ||
Oncolytics Biotech Inc. is driven by a powerful mission: to transform the lives of cancer patients by redefining the way cancer is treated. With a deep commitment to advancing oncolytic virotherapy, the company aims to provide more effective and personalized treatment options that maximize therapeutic outcomes. By leveraging the body's own immune system and developing targeted therapies, Oncolytics Biotech seeks to revolutionize the field of oncology and improve patient outcomes worldwide. | Oncolytics Biotech Inc. is driven by a powerful mission: to transform the lives of cancer patients by redefining the way cancer is treated. With a deep commitment to advancing oncolytic virotherapy, the company aims to provide more effective and personalized treatment options that maximize therapeutic outcomes. By leveraging the body's own immune system and developing targeted therapies, Oncolytics Biotech seeks to revolutionize the field of oncology and improve patient outcomes worldwide. | ||
== Product | == Product == | ||
Oncolytics’ core product is '''Pelareorep,''' a cutting-edge intravenously delivered immunotherapeutic agent aiming to treat solid tumours and hematological malignancies'''.''' Oncolytics Biotech. is testing Pelareorep as a potential treatment as the immune system has difficulty recognising and destroying malignant cancerous cells. It can be used alone or for more successful results, in combination with other chemotherapeutic drugs such as Paclitaxel | Oncolytics’ core product is '''Pelareorep,''' a cutting-edge intravenously delivered immunotherapeutic agent aiming to treat solid tumours and hematological malignancies'''.''' Oncolytics Biotech. is testing Pelareorep as a potential treatment as the immune system has difficulty recognising and destroying malignant cancerous cells. It can be used alone or for more successful results, in combination with other chemotherapeutic drugs such as Paclitaxel, or immunotherapies such as CAR T, targeting a large market audience. | ||
Cancer cells (tumour cells) are unique in comparison to other cells in the body as they can rapidly multiply due to their ability to carry out a cell signalling pathway, namely the '''RAS-activated pathway''' | Cancer cells (tumour cells) are unique in comparison to other cells in the body as they can rapidly multiply due to their ability to carry out a cell signalling pathway, namely the '''RAS-activated pathway'''. As a proprietary isolate of the naturally occurring, non-pathogenic double-stranded RNA (dsRNA) virus reovirus, Pelareorep can target this pathway. '''Reoviruses''' are a group of RNA double stranded viruses possessing the ability to recognise unique glycans on cancerous cells via the σ1R protein to allow immune system enhancement. The RAS-activated pathway required for Pelareorep to function is only present in cancerous cells, this includes some of the most common cancers such as lung and breast cancer. | ||
Its mechanism of action involves the activation of both the innate and adaptive immune systems while weakening tumor defense mechanisms | Its mechanism of action involves the activation of both the innate and adaptive immune systems while weakening tumor defense mechanisms. This effect enhances the immune system's ability to combat cancer, rendering tumors more susceptible to a diverse range of oncology treatments. Pelareorep is injected intravenously, once it interacts with a RAS-activated cancer cells it rapidly multiplies which causes: | ||
* Release of cytokines (innate) | * Release of cytokines (innate) | ||
* Activation of Natural Killer cells (innate) | * Activation of Natural Killer cells (innate) | ||
* Dendritic cell activation (innate) | * Dendritic cell activation (innate) | ||
* '''T cell education and activation''' | * '''T cell education and activation''' (adaptive) | ||
* Tumour cell lysis | * Tumour cell lysis | ||
* Activation of the interferon-gamma (IFN-γ) signalling pathway | * Activation of the interferon-gamma (IFN-γ) signalling pathway | ||
After the cell has burst all of the daughter Pelareorep cells are released to continue the process in surrounding cancer cells with the same glycans, until all cancerous cells have been defeated. | After the cell has burst all of the daughter Pelareorep cells are released to continue the process in surrounding cancer cells with the same glycans, until all cancerous cells have been defeated. | ||
Pelareorep has been clinically tested in partnership with Canadian Cancer Trials Group for pancreatic, breast, head, neck, prostate, lung, colorectal, bladder and ovarian cancers. Breast and pancreatic cancer tests have shown statistically significant results and have moved to Phase III clinical trials, on track for licence enabling studies. The clinical tests have also shown '''low death rates and less adverse side effects''' in comparison to chemotherapy. Side effects are: chills, fever, headache, cough, myalgia, runny nose, sore throat, fatigue, lymphopenia or neutropenia all for less than 6 hours. | Pelareorep has been clinically tested in partnership with Canadian Cancer Trials Group for pancreatic, breast, head, neck, prostate, lung, colorectal, bladder and ovarian cancers. Breast and pancreatic cancer tests have shown statistically significant results and have moved to Phase III clinical trials, on track for licence enabling studies. The clinical tests have also shown '''low death rates and less adverse side effects''' in comparison to chemotherapy. Side effects are: chills, fever, headache, cough, myalgia, runny nose, sore throat, fatigue, lymphopenia or neutropenia all for less than 6 hours. | ||
| Line 92: | Line 60: | ||
* Selectively destroys tumour cells, not normal, healthy cells | * Selectively destroys tumour cells, not normal, healthy cells | ||
* It has a predictive biomarker- peripheral T-cell clonality | * It has a predictive biomarker- peripheral T-cell clonality | ||
Pelareorep is manufactured at a commercial scale under a commercial supply agreement with '''MilliporeSigma''' (formerly Sigma-Aldrich) | Pelareorep is manufactured at a commercial scale under a commercial supply agreement with '''MilliporeSigma''' (formerly Sigma-Aldrich). At the moment, Pelareorep is mainly supplied to Canada and the US, however the company is looking to expand to other countries with 17 pending patent applications. | ||
Currently the price of Pelareorep is unknown as it isn't officially a marketed drug, but it is likely to be equivalent to the price of Pfizer's Paclitaxel at '''$18 for a supply of 5 millilitres.''' | Currently the price of Pelareorep is unknown as it isn't officially a marketed drug, but it is likely to be equivalent to the price of Pfizer's Paclitaxel at '''$18 for a supply of 5 millilitres.''' | ||
| Line 145: | Line 113: | ||
'''Angela Holtham, MBA,''' is a '''Director''' at Oncolytics. She is currently the Senior Vice President and Chief Financial Officer of Canadian subsidiary of Nabisco Inc. She has also been the Vice President, Finance and Chief Financial Officer in the Ontario-based Hospital for Sick Children. | '''Angela Holtham, MBA,''' is a '''Director''' at Oncolytics. She is currently the Senior Vice President and Chief Financial Officer of Canadian subsidiary of Nabisco Inc. She has also been the Vice President, Finance and Chief Financial Officer in the Ontario-based Hospital for Sick Children. | ||
== Major Stakeholders in Oncolytics Biotech:- <ref>https://www.capitaliq.com/CIQDotNet/Ownership/CompanySummary.aspx?CompanyId=1340759</ref> == | == Major Stakeholders in Oncolytics Biotech:- <ref>https://www.capitaliq.com/CIQDotNet/Ownership/CompanySummary.aspx?CompanyId=1340759</ref> == | ||
| Line 183: | Line 148: | ||
|} | |} | ||
== Risks | == Risks == | ||
As with any investment, investing in Oncolytics Biotech carries a level of risk. Overall, based on the key risks highlighted below, the degree of risk associated with an investment in Oncolytics Biotech is very high. | As with any investment, investing in Oncolytics Biotech carries a level of risk. Overall, based on the key risks highlighted below, the degree of risk associated with an investment in Oncolytics Biotech is very high. | ||
| Line 208: | Line 173: | ||
* Market prices for securities of biotechnology companies generally are volatile, and may or may not move in a manner consistent with the progress made__INDEX__ | * Market prices for securities of biotechnology companies generally are volatile, and may or may not move in a manner consistent with the progress made__INDEX__ | ||
== Relative Valuation== | == Relative Valuation== | ||
| Line 315: | Line 185: | ||
! colspan="2" |Valuation (x) | ! colspan="2" |Valuation (x) | ||
|- | |- | ||
|Company | |||
|Ticker | |||
| Price | |||
|Shares Out | |||
|Market Cap | |||
| TEV | |||
|Revenue | |||
|EBITDA | |||
| EBIT | |||
|Net Income | |||
|Assets | |||
|Liabilities | |||
|Book Value | |||
|R&D Exp. | |||
| P/B | |||
| EV/R&D | |||
|- | |- | ||
|<u>Oncolytics Biotech Inc.</u> | |<u>Oncolytics Biotech Inc.</u> | ||
| Line 474: | Line 344: | ||
|Helix BioPharma Corp. | |Helix BioPharma Corp. | ||
|Helix BioPharma Corp., an immune-oncology company in Canada, is developing L-DOS47 and V-DOS47 for non-small cell lung cancer treatment. They have collaboration agreements with Moffitt Cancer Center to investigate pharmacodynamics, benefits of combination therapy, and with and University Hospital Tuebingen to assess therapeutic response in cancer models expressing CEACAM6. | |Helix BioPharma Corp., an immune-oncology company in Canada, is developing L-DOS47 and V-DOS47 for non-small cell lung cancer treatment. They have collaboration agreements with Moffitt Cancer Center to investigate pharmacodynamics, benefits of combination therapy, and with and University Hospital Tuebingen to assess therapeutic response in cancer models expressing CEACAM6. | ||
|} | |} | ||
== References == | == References<ref>https://pubmed.ncbi.nlm.nih.gov/25693885/</ref> == | ||
<references /> | <references /> | ||